AU Patent

AU2013228033A1 — Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Assigned to Abbott GmbH and Co KG · Expires 2013-10-03 · 13y expired

What this patent protects

A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.

USPTO Abstract

A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013228033A1
Jurisdiction
AU
Classification
—
Expires
2013-10-03
Drug substance claim
No
Drug product claim
No
Assignee
Abbott GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.